Skip to main content
SpringerLink
Log in

Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The natural killer (NK) and lymphokine-activated killer (LAK) cell activities of peripheral blood lymphocytes from chronic myeloid leukemia (CML) patients in remission and from healthy donors have been studied. Regression analysis to compare both cytotoxic responses in individual donors and the frequency of LAK cell precursors was also carried out. About 42% of CML patients in remission showed low NK activity (less than the mean percentage NK activity of healthy donors — 2 SD) and were categorised as low NK responders. The stage of remission or the drugs used to bring about remission did not influence the NK status. The LAK activity of low NK as well as normal NK responder CML patients was significantly low against the NK-sensitive K562 cell line and the NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumor targets, as assessed by linear regression analysis. Allogeneic leukemic cells were more resistant to killing, especially by patients' LAK cells. The frequency analysis of LAK cell precursors revealed a significant reduction in the LAK cell progenitor frequency in CML patients in remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB (1988) Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71: 709

    Google Scholar 

  2. Cordingley FT, Hoffbrand AV, Brenner MK (1988) Cytokineinduced enhancement of the susceptibility of hairy cell leukemia lymphocytes to natural killer cell lysis. Br J Haematol 70: 37

    Google Scholar 

  3. Dabholkar M, Advani S, Tatake R, Gangal S (1986) Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission. Leukemia Res 10: 203

    Google Scholar 

  4. Dabholkar M, Tatake R, Amin K, Advani S, Gangal S (1989) Modulation of natural killer and antibody-dependent cellular cytotoxicity by Interferon and Interleukin-2 in chronic myeloid leukemia patients in remission. Oncology 46: 123

    Google Scholar 

  5. Dawson MM, Johnston D, Taylor GM, Moore M (1986) Lymphokine activated killing of fresh human leukemias. Leukemia Res 10: 683

    Google Scholar 

  6. Fierro MT, Liao X-S, Lusso P, Bonferoni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R (1988) In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2: 50

    Google Scholar 

  7. Fujimiya Y, Bakke A, Chang WC, Linker-Israeli M, Udis B, Horwitz D, Pattengale PK (1986) Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1. Int J Cancer 37: 639

    Google Scholar 

  8. Grimm EA (1986) Human lymphokine activated killer (LAK) cells as a potential immunotherapeutic modality. Biochim Biophys Acta 865: 267

    Google Scholar 

  9. Haggerty J, Hess A, Vogelsang G, Burke P, Santos G (1987) Effect of lymphokine activated killer (LAK) cells on human leukemia in vitro (meeting abstr). Proc Ann Meet Am Assoc Cancer Res 28: 228

    Google Scholar 

  10. Hsieh KH, Shu S, Lee CS, Chu CT, Yang CS, Chang KJ (1987) Lysis of primary hepatic tumors by lymphokine activated killer cells. Gut 28: 117

    Google Scholar 

  11. Lin C-C, Kuo Y-C, Huang W-C, Lin C-Y (1987) Natural killer cell activity in lung cancer patients. Chest 92: 1022

    Google Scholar 

  12. Lotzova E (1987) Interleukin-2 generated killer cells, their characterisation and role in cancer therapy. Cancer Bull 39: 30

    Google Scholar 

  13. Morikawa Y, Watanabe S, Kodama T (1987) Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells. Jpn J Clin Oncol 17: 129

    Google Scholar 

  14. Ortaldo JR (1987) Regulation of natural killer activity. Cancer Metastasis Rev 6: 637

    Google Scholar 

  15. Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164: 1193

    Google Scholar 

  16. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin-2 activated lymphocytes for leukemia and lymphoma cells. Blood 68: 938

    Google Scholar 

  17. Pawelec G, Schmidt H, Schneider E, Buhring H-J, Ehninger G (1988) Cellular immunological defects of chronic myeloid leukemia: partial dependence on busulphan therapy. Cancer Immunol Immunother 27: 89

    Google Scholar 

  18. Petrie A (1987) Linear Regression and Correlation. In: Petrie A (ed) Lecture notes on medical statistics. Blackwell Scientific Publications, London, p 102

    Google Scholar 

  19. Phillips JH, Lanier LL (1986) Dissection of the lymphokineactivated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814

    Google Scholar 

  20. Rosenberg SA (1986) Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In. DeVita VT, Hellman S, Rosenberg S (eds) Important advances in oncology. J. B. Lippincott Co., Philadelphia, p 55

    Google Scholar 

  21. Rosenberg SA (1988) Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: DeVita VT, Hellmann S, Rosenberg SA (eds) Important advances in oncology. J. B. Lippincott Co., Philadelphia, p 217

    Google Scholar 

  22. Saranath D, Mukhopadhyaya R, Rao RS, Fakih AR, Naik SL, Gangal SG (1985) Cell mediated immune status in patients with squamous cell carcinoma of the oral cavity. Cancer 56: 1062

    Google Scholar 

  23. Smith BR, Rosenthal DS, Ault KA (1985) Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity. Exp Hematol 13: 189

    Google Scholar 

  24. Tahara T, Iseki R, Morishima Y, Yokomaku S, Ohno R, Saito H (1988) Generation and characterisation of lymphokine activated killer cells against fresh human leukemia cells. Jpn J Cancer Res (Gann) 79: 390

    Google Scholar 

  25. Tatake RJ, Krishnan N, Rao RS, Fakih AR, Gangal SG (1989) Lymphokine activated killer cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer. Int J Cancer 43: 560

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunology Division, Cancer Research Institute, Tata Memorial Centre, 400 012, Parel, Bombay, India

    Nirmala Rajaram, Revati J. Tatake, Sanjeev L. Naik & Sudha G. Gangal (Head)

  2. Tata Memorial Hospital, Tata Memorial Centre, 400 012, Bombay, India

    Suresh H. Advani

Authors
  1. Nirmala Rajaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Revati J. Tatake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suresh H. Advani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sanjeev L. Naik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sudha G. Gangal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajaram, N., Tatake, R.J., Advani, S.H. et al. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia. Cancer Immunol Immunother 31, 44–48 (1990). https://doi.org/10.1007/BF01742494

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01742494

Keywords

Search

Navigation